125 related articles for article (PubMed ID: 38886718)
1. Cost-utility analysis of an alcohol policy in Thailand: a case study of a random breath testing intervention.
Vichitkunakorn P; Khampang R; Leelahavarong P; Nontarak J; Assanangkornchai S
BMC Health Serv Res; 2024 Jun; 24(1):739. PubMed ID: 38886718
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of interventions for reducing road traffic injuries related to driving under the influence of alcohol.
Ditsuwan V; Lennert Veerman J; Bertram M; Vos T
Value Health; 2013; 16(1):23-30. PubMed ID: 23337212
[TBL] [Abstract][Full Text] [Related]
3. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
[TBL] [Abstract][Full Text] [Related]
4. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
Tantai N; Chaikledkaew U; Tanwandee T; Werayingyong P; Teerawattananon Y
BMC Health Serv Res; 2014 Apr; 14():170. PubMed ID: 24731689
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
7. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.
Permsuwan U; Thongprasert S; Sirichanchuen B
Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand.
Saokaew S; Permsuwan U; Chaiyakunapruk N; Nathisuwan S; Sukonthasarn A; Jeanpeerapong N
Thromb Res; 2013 Oct; 132(4):437-43. PubMed ID: 24041634
[TBL] [Abstract][Full Text] [Related]
9. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.
Leelahavarong P; Chaikledkaew U; Hongeng S; Kasemsup V; Lubell Y; Teerawattananon Y
BMC Health Serv Res; 2010 Jul; 10():209. PubMed ID: 20633303
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of transcatheter aortic valve implantation versus surgery in severe aortic stenosis patients with intermediate surgical risk in Thailand.
Permsuwan U; Yoodee V; Buddhari W; Wongpraparut N; Thonghong T; Cheewatanakornkul S; Meemook K; Sakiyalak P; Duangpakdee P; Yadee J
J Geriatr Cardiol; 2022 Nov; 19(11):822-832. PubMed ID: 36561052
[TBL] [Abstract][Full Text] [Related]
11. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
Niyomsri S; Nimworapan M; Wongcharoen W; Dilokthornsakul P
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833871
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.
Sriphoosanaphan S; Pantumongkol W; Kulpeng W; Charonpongsuntorn C; Tanwandee T; Sukeepaisarnjaroen W; Sobhonslidsuk A; Tangkijvanich P
PLoS One; 2024; 19(3):e0300327. PubMed ID: 38512900
[TBL] [Abstract][Full Text] [Related]
13. Cost-Utility Analysis of Transcatheter Aortic Valve Implantation versus Surgery in High-Risk Severe Aortic Stenosis Patients in Thailand.
Permsuwan U; Yoodee V; Buddhari W; Wongpraparut N; Thonghong T; Cheewatanakornkul S; Meemook K; Sakiyalak P; Duangpakdee P; Yadee J
Clinicoecon Outcomes Res; 2022; 14():487-498. PubMed ID: 35909499
[TBL] [Abstract][Full Text] [Related]
14. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
15. Cost-Utility and Cost-Effectiveness Analysis of Spinal Cord Stimulation for Chronic Refractory Pain in the Context of Developing Country.
Zinboonyahgoon N; Saengsomsuan N; Chaikittiporn N; Wangnamthip S; Kositamongkol C; Phisalprapa P
Pain Physician; 2023 Jan; 26(1):69-79. PubMed ID: 36791296
[TBL] [Abstract][Full Text] [Related]
16. Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
Krittayaphong R; Permsuwan U
Am J Cardiovasc Drugs; 2022 Sep; 22(5):577-590. PubMed ID: 35796952
[TBL] [Abstract][Full Text] [Related]
17. Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program.
Sruamsiri R; Chaiyakunapruk N; Pakakasama S; Sirireung S; Sripaiboonkij N; Bunworasate U; Hongeng S
BMC Health Serv Res; 2013 Feb; 13():45. PubMed ID: 23379888
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.
Kulpeng W; Sompitak S; Jootar S; Chansung K; Teerawattananon Y
Clin Ther; 2014 Apr; 36(4):534-43. PubMed ID: 24635968
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness analysis of national smoking cessation services among chronic obstructive pulmonary disease patients in Thailand.
Prasitwarachot R; Thavorn K; Patikorn C; Wattanasirichaigoon S; Rungruanghiranya S; Thongphiew A; Chaiyakunapruk N
J Med Econ; 2023; 26(1):1377-1385. PubMed ID: 37818930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
